Pave the road to successful commercialization of your radiopharmaceutical innovation with CARI – The CPDC & adMare Radiopharmaceutical Initiative
September 30 2020

If you are an academic researcher or a biotech company looking to pave the road to successful commercialization of your radiopharmaceutical innovation, join us on October 15th, 2020.
What is CARI?
CARI is a collaboration between The Centre for Probe Development and Commercialization (CPDC) and adMare BioInnovations (adMare) where we will bring respective resources together to advance an area of tremendous therapeutic and commercial potential in which Canada can gain considerable global competitive advantage: RADIOPHARMACEUTICALS. The objective of CARI, is for CPDC and adMare to seek out and uncover radiopharmaceutical opportunities arising from academic discoveries and early enterprises, establish rigorous drug development programs around selected opportunities, and drive the generation of proof-of-principle and other data supportive of the commercialization of new radiopharmaceutical assets.